logo-loader
Verona Pharma

Verona Pharma can make real difference to COPD market believes CEO Karlsson

Jan-Anders Karlsson says the recent strengthening of its management team has given Verona Pharma  PLC (LON:VRP) the experience to take its respiratory disease treatment Ensifentrine to market.

The COPD drug is undergoing a phase IIb trial with 400 very severe sufferers who use a nebulizer.

Results are expected around the end of the year and Karlsson, the Aim and Nasdaq-listed group’s chief executive, believes Ensifentrine can make a real difference both to people with severe forms of the disease and earlier-stage sufferers.

“It’s a new mechanism, a new compound and a new mode of action,” he tells Proactive’s Andrew Scott.

“We can help people who have nowhere else to go.”

Talks are already ongoing with possible partners about commercialising the drug, though Karlsson believes Verona can market it on its own in the US.

“It’s elsewhere we will need some help,” he says.

Quick facts: Verona Pharma

Price: 47 GBX

Market: AIM
Market Cap: £49.5 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Verona Pharma named herein, including the promotion by the Company of Verona Pharma in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Ensifentrine offers real benefit to COPD sufferers believes Verona Pharma...

Verona Pharma PLC (LON:VRP) has a huge twelve months ahead for its COPD treatment ensifentrine, chief executive Jan-Anders Karlsson tells Proactive.  Recent phase II trial data indicated that a new dry powder formulation significantly improved the breathing and the lung condition of less...

on 19/9/19

2 min read